Biomerica

Biomerica Interest Coverage

The Interest Coverage Ratio of Biomerica (BMRA) as of Oct 26, 2026 is -31.13. In the previous year, Interest Coverage Ratio was -14.77 — a change of 110.75% (lower).

Interest Coverage

-31.13

YoY

110.75%

Last updated:

Interest Coverage Ratio of Biomerica is 2025 -31.13 . Interest Coverage Ratio of Biomerica was 2024 -14.77 . It decreases by 110.75% lower compared to the previous year.

The Biomerica Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2018
-29.64 USD
Jan 1, 2019
-60.32 USD
Jan 1, 2020
-34.33 USD
Jan 1, 2021
-107.14 USD
Jan 1, 2022
-151.13 USD
Jan 1, 2023
-55.56 USD
Jan 1, 2024
-14.77 USD
Jan 1, 2025
-31.13 USD
The Biomerica Interest Coverage history
YEARInterest CoverageYoY
-31.13+110.75%
-14.77-73.41%
-55.56-63.24%
-151.13+41.06%
-107.14+212.12%
-34.33-43.09%
-60.32+103.54%
-29.64+55.22%
-19.09-53.82%
-41.35+23.32%
-33.53+50.16%
-22.33—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biomerica Stock analysis

What does Biomerica do? Biomerica, Inc. generates revenue through the development, manufacture, and marketing of medical diagnostic products for early detection and monitoring of chronic diseases. The company sells diagnostic test kits to clinical laboratories and point-of-care markets, analyzing blood, urine, or fecal specimens to measure specific bacteria, hormones, antibodies, antigens, or other substances. Its flagship product, InFoods IBS, offers diagnostic-guided therapy to identify patient-specific foods that may alleviate Irritable Bowel Syndrome symptoms when removed from the diet. The diagnostic test kits are used by clinical laboratories and point-of-care facilities to detect diseases through specimen analysis. InFoods IBS targets physicians seeking personalized dietary solutions for IBS patients, allowing them to identify foods that improve symptoms when eliminated. Biomerica focuses on chronic disease management with products designed for early detection and monitoring in both laboratory and point-of-care settings. Biomerica's revenue streams include sales of diagnostic test kits to clinical laboratories and point-of-care markets, as well as the InFoods IBS diagnostic-guided therapy product. The company serves healthcare providers and physicians who utilize these tools for patient diagnosis and treatment planning, particularly in managing chronic conditions like IBS through dietary adjustments. Biomerica is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biomerica stock

Interest Coverage Ratio of Biomerica is -31.13 in 2025.

Interest Coverage Ratio of Biomerica changed from -14.77 to -31.13, representing a 110.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Biomerica since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Biomerica with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Biomerica

All Key Metrics — Biomerica